Later menopause and long-term use of hormone therapy linked to higher risk of hearing loss
Hearing loss risk is higher in women who go through the menopause after 50 years of age and take hormone therapy for five years or more.
Reduced oestrogen levels post-menopause have been associated with hearing loss and postmenopausal hormone therapy, (HT) with slow hearing decline, but findings from a new study suggest otherwise.
A prospective cohort study, published in Menopause (8 May 2017), followed 80,972 women (baseline age: 27–44 years) for 22 years.
Hearing loss was reported in 18,558 cases. For women who underwent natural menopause aged 50 or older, hearing loss risk was 10% higher than for those who were under 50 (multivariable-adjusted relative risk [MVRR] 1.10, 95% confidence interval [CI] 1.03, 1.17). Among postmenopausal women, use of HT over 10+ years was associated with a 21% higher risk of hearing loss compared with no use (MVRR 1.21 95% CI 1.07, 1.37) while use for 5–9.9 years was associated with a 15% increased risk (MVRR 1.15 95% CI 1.06, 1.24).
The researchers conclude that hearing health could be considered by women evaluating the risks and benefits of HT.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20202837
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com